$708 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 66 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OTLKW | Exit | OUTLOOK THERAPEUTICS INC*w exp 02/18/202 | $0 | – | -129,500 | -100.0% | -0.00% | – |
| LVTX | Exit | LAVA THERAPEUTICS NV | $0 | – | -137,857 | -100.0% | -0.08% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -4,411 | -100.0% | -0.11% | – |
| CYT | Exit | CYTEIR THERAPEUTICS INC | $0 | – | -98,860 | -100.0% | -0.12% | – |
| DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -105,204 | -100.0% | -0.14% | – |
| ANNX | Exit | ANNEXON INC | $0 | – | -123,637 | -100.0% | -0.16% | – |
| ARGX | Exit | ARGENX SEsponsored adr | $0 | – | -4,291 | -100.0% | -0.16% | – |
| Exit | ARYA SCIENCES ACQUISITN CORP | $0 | – | -200,000 | -100.0% | -0.21% | – | |
| QURE | Exit | UNIQURE NVcall | $0 | – | -100,000 | -100.0% | -0.23% | – |
| BLSA | Exit | BCLS ACQUISITION CORP | $0 | – | -216,250 | -100.0% | -0.23% | – |
| CMPX | Exit | COMPASS THERAPEUTICS INC | $0 | – | -700,000 | -100.0% | -0.24% | – |
| ACET | Exit | ADICET BIO INC | $0 | – | -150,000 | -100.0% | -0.29% | – |
| INBX | Exit | INHIBRX INC | $0 | – | -61,931 | -100.0% | -0.30% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -13,000 | -100.0% | -0.34% | – |
| TPTX | Exit | TURNING POINT THERAPEUTICS I | $0 | – | -68,734 | -100.0% | -0.36% | – |
| PNT | Exit | POINT BIOPHARMA GLOBAL INC | $0 | – | -592,592 | -100.0% | -0.36% | – |
| CAMT | Exit | CAMTEK LTDord | $0 | – | -75,000 | -100.0% | -0.38% | – |
| BCAB | Exit | BIOATLA INC | $0 | – | -180,006 | -100.0% | -0.39% | – |
| Exit | OMEGA THERAPEUTICS INC | $0 | – | -352,948 | -100.0% | -0.44% | – | |
| ALLT | Exit | ALLOT LTD | $0 | – | -340,912 | -100.0% | -0.44% | – |
| KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -316,200 | -100.0% | -0.46% | – |
| STRO | Exit | SUTRO BIOPHARMA INC | $0 | – | -281,702 | -100.0% | -0.46% | – |
| PMVP | Exit | PMV PHARMACEUTICALS INC | $0 | – | -190,525 | -100.0% | -0.48% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -281,769 | -100.0% | -0.59% | – |
| IDYA | Exit | IDEAYA BIOSCIENCES INC | $0 | – | -235,695 | -100.0% | -0.61% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -422,461 | -100.0% | -0.66% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -166,766 | -100.0% | -0.71% | – |
| ZLAB | Exit | ZAI LAB LTDadr | $0 | – | -111,641 | -100.0% | -0.77% | – |
| ASAN | Exit | ASANA INCcl a | $0 | – | -96,500 | -100.0% | -0.79% | – |
| GRPH | Exit | GRAPHITE BIO INC | $0 | – | -663,194 | -100.0% | -0.91% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INCcall | $0 | – | -250,000 | -100.0% | -0.94% | – |
| LESL | Exit | LESLIES INC | $0 | – | -372,569 | -100.0% | -0.97% | – |
| ARYD | Exit | ARYA SCIENCES ACQU CORP IVcl a | $0 | – | -1,000,000 | -100.0% | -1.09% | – |
| VRNT | Exit | VERINT SYS INC | $0 | – | -200,000 | -100.0% | -1.16% | – |
| BURL | Exit | BURLINGTON STORES INC | $0 | – | -41,501 | -100.0% | -1.33% | – |
| PANW | Exit | PALO ALTO NETWORKS INC | $0 | – | -24,000 | -100.0% | -1.47% | – |
| FB | Exit | META PLATFORMS INCcl a | $0 | – | -41,622 | -100.0% | -1.54% | – |
| AMZN | Exit | AMAZON COM INC | $0 | – | -4,200 | -100.0% | -1.54% | – |
| MSFT | Exit | MICROSOFT CORP | $0 | – | -50,536 | -100.0% | -1.87% | – |
| Exit | WIX COM LTDnote 8/1 | $0 | – | -18,959,000 | -100.0% | -1.91% | – | |
| XBI | Exit | SPDR SER TRcall | $0 | – | -220,000 | -100.0% | -2.71% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.